Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02737787 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT02737787: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT02737787 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 11 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02737787, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety of a combination of an investigational WT1 vaccine and another drug called nivolumab. This is the first time that the WT1 vaccine and nivolumab are being used in combination. Also, to test the safety of a combination of an investigational NY-ESO-1 vaccine and another drug called nivolumab.
Interventions
- DRUG Nivolumab
- BIOLOGICAL WT1 Vaccine
- BIOLOGICAL NY-ESO-1 Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2016-04 |
| Est. Completion | 2023-04-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02737787
The ClinicalTrials.gov registry entry for NCT02737787 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Nivolumab is the first listed.
NCT02737787 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02737787 about?
NCT02737787 is a clinical study titled "A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer". The purpose of this study is to test the safety of a combination of an investigational WT1 vaccine and another drug called nivolumab. This is the first time that the WT1 vaccine and nivolumab are being used in combination. Also, to test the safety of a combination of an investigational NY-ESO-1 vacc...
What is the current status of trial NCT02737787?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2016-04. Estimated completion is 2023-04-06.
What interventions are being tested in trial NCT02737787?
The interventions under investigation include: Nivolumab (DRUG), WT1 Vaccine (BIOLOGICAL), NY-ESO-1 Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT02737787?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.